An analysis of the relationship between autoantibodies andclinical findings in patients with systemic sclerosis

Yayla, Müçteba Enes; İlgen, Ufuk; Düzgün, Nurşen

doi:10.3906/sag-1708-67

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the frequency of autoantibodies may vary by ethnicity, and data on SSc-specific autoantibodies from Turkey are limited to the frequencies of anti-Scl70 and anti-centromere antibodies [26]. In addition, in only one study, the frequency of RNAPIII antibodies was reported as 2.2%, which was lower than our results [27]. The difference in results may be because the previous study was conducted in patients with extensive SSc and long disease duration or because the two studies' antibody analysis methods were different.…”

Section: Discussioncontrasting

confidence: 95%

Extended Autoantibody Panel in Turkish Patients with Early-Stage Systemic Sclerosis: Co-expressions and Their Influences on Clinical Phenotypes

Karadag,

Komac,

Erez

et al. 2024

Preprint

View full text Add to dashboard Cite

Background/aim: To investigate the frequency and clinical relevance of an extended autoantibody (ab) profile in patients with SSc. Materials and Methods: In this cross-sectional study, serum from 100 consecutive patients was subjected to indirect immunofluorescence (HEp-20-10/primate liver mosaic) and Systemic Sclerosis Profile by EUROIMMUN (Lübeck, Germany) to evaluate ANA and autoantibodies against 13 different autoantibodies in patients with SSc less than three years. Results: 93 of 100 patients were positive for ANA by indirect immunofluorescence (IIF). The prevalence of Anti-Scl70 ab was 41%, anti-centromere (ACA) 27%, and anti-RNA polymerase (RNAPIII) 15%. Scl70 was more associated with diffuse subtype (p<0.001), ILD (p<0.001), and high mRSS (p=0.002); ACA with limited disease (p<0.001), less ILD (p<0.001), overlap (p=0.017) and low mRSS (p=0.024); RNAPIII with diffuse disease (p=0.027), ILD (p=0.016) and high mRSS (p=0.001). Fifty-three patients showed single positivity (26 anti-Scl70, 16 ACA, 6 anti-RNAPIII, 1 anti-Ku ab, 1 anti-PM/Scl100, 2 anti-PM/Scl75, 1 anti-Ro52), whereas 32 patients had multiple auto-antibody positivities. Among common SSc-specific autoantibodies, Scl70 and RNAPIII showed the highest co-occurrence (n=4). One patient was simultaneously positive for anti-RNAPIII ab and ACA, and one was positive for ACA and Scl70. The clinical features were not statistically different between single and multiple autoantibody-positivity for common SSc-specific autoantibodies (ACA, Scl70, and RNAP III), except for digital ulcer in multi-antibody positive ACA group (p=0.019). Conclusion: Based on our results, co-expression of auto-antibodies is not uncommon in SSc patients. Although SSc-specific auto-antibodies generally show known clinical features, the clinical presentation of the co-expression in specific and non-specific auto-antibody positivity continues to be important.

show abstract

Section: Discussioncontrasting

confidence: 95%

Extended Autoantibody Panel in Turkish Patients with Early-Stage Systemic Sclerosis: Co-expressions and Their Influences on Clinical Phenotypes

Karadag,

Komac,

Erez

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…However, the frequency of autoantibodies may vary by ethnicity, and data on SSc‐specific autoantibodies from Turkey are limited to the frequencies of anti‐Scl70 and anti‐centromere abs 23 . In addition, in only one study, the frequency of anti‐RNAPIII antibodies was reported as 2.2%, which was lower than our results 24 . The difference in results may be because the previous study was conducted in patients with extensive SSc and long disease duration or because the two studies' antibody analysis methods were different.…”

Section: Discussioncontrasting

confidence: 94%

“… 23 In addition, in only one study, the frequency of anti‐RNAPIII antibodies was reported as 2.2%, which was lower than our results. 24 The difference in results may be because the previous study was conducted in patients with extensive SSc and long disease duration or because the two studies' antibody analysis methods were different.…”

Section: Discussionmentioning

confidence: 99%

Extended autoantibody panel in Turkish patients with early‐stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes

Temiz Karadağ,

Komac,

Erez

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background/AimTo investigate the frequency and clinical relevance of an extended autoantibody profile in patients with systemic sclerosis (SSc).Materials and MethodsIn this cross‐sectional study, serum from 100 consecutive patients was subjected to indirect immunofluorescence (IIF) (HEp‐20‐10/primate liver mosaic) and Systemic Sclerosis Profile by EUROIMMUN to evaluate anti‐nuclear antibodies (ANA) and autoantibodies against 13 different autoantibodies in patients with SSc less than 3 years.ResultsNinety‐three of 100 patients were positive for ANA by IIF. Fifty‐three patients showed single positivity, 26 anti‐topoisomerase antibodies (anti‐Scl70 ab), 16 anticentromere antibodies (ACAs), six anti‐RNA polymerase III antibodies (anti‐RNAPIII ab), one anti‐Ku antibody, one anti‐PM/Scl100 antibody, two anti‐PM/Scl75 antibodies, one anti‐Ro52 antibody, whereas 32 patients had multiple autoantibody positivities. Among classic SSc‐specific autoantibodies, anti‐Scl70 and anti‐RNAPIII abs showed the highest cooccurrence (n = 4). One patient was simultaneously positive for anti‐RNAPIII ab and ACA, and one was positive for ACA and anti‐Scl70 ab. The clinical features were not statistically different between single and multiple autoantibody‐positivity for classic SSc‐specific autoantibodies (ACA, anti‐Scl70 ab, and anti‐RNAPIII ab), except for digital ulcer in the multiantibody positive ACA group (p = .019).ConclusionBased on our results, coexpression of autoantibodies is not uncommon in SSc patients. Although autoantibodies specific to SSc in early disease show generally known clinical features, it remains to be investigated how the coexpression of autoantibodies will affect clinical presentation.

show abstract

Prevalence of anti-Ro52-kDa/SSA (TRIM21) antibodies and associated clinical phenotype in systemic sclerosis: Data from a French cohort, a systematic review and meta-analysis

Martel,

Leurs,

Launay

et al. 2024

Autoimmunity Reviews

View full text Add to dashboard Cite

An analysis of the relationship between autoantibodies andclinical findings in patients with systemic sclerosis

Cited by 4 publications

References 22 publications

Extended Autoantibody Panel in Turkish Patients with Early-Stage Systemic Sclerosis: Co-expressions and Their Influences on Clinical Phenotypes

Extended Autoantibody Panel in Turkish Patients with Early-Stage Systemic Sclerosis: Co-expressions and Their Influences on Clinical Phenotypes

Extended autoantibody panel in Turkish patients with early‐stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes

Prevalence of anti-Ro52-kDa/SSA (TRIM21) antibodies and associated clinical phenotype in systemic sclerosis: Data from a French cohort, a systematic review and meta-analysis

Contact Info

Product

Resources

About